Achieve Life Sciences (ACHV) Stock Overview
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ACHV Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Achieve Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.79 |
| 52 Week High | US$6.15 |
| 52 Week Low | US$2.00 |
| Beta | 2.25 |
| 1 Month Change | 60.39% |
| 3 Month Change | 37.86% |
| 1 Year Change | 112.09% |
| 3 Year Change | -19.02% |
| 5 Year Change | -37.67% |
| Change since IPO | -99.34% |
Recent News & Updates
Recent updates
Regulatory And Commercial Hurdles Will Test Smoking Cessation Catalyst Yet Long Term Potential Remains
Catalysts About Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company focused on bringing cytisinicline, a nicotine dependence treatment, to market for smoking and vaping cessation. What are the underlying business or industry changes driving this perspective?
Regulatory Tailwinds And Public Health Demand Will Support This Nicotine Cessation Opportunity
Catalysts About Achieve Life Sciences Achieve Life Sciences is a clinical stage biopharmaceutical company focused on developing cytisinicline as a treatment for nicotine dependence in smokers and vapers. What are the underlying business or industry changes driving this perspective?
FDA Priority Voucher And Smoking Cessation Tailwinds Will Transform This Undervalued Biotech Story
Catalysts About Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence in smokers and people who vape. What are the underlying business or industry changes driving this perspective?Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy
Summary Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline demonstrates superior efficacy and safety versus current treatments, with strong precedent in Europe and a large, underserved U.S. market. ACHV’s market cap (~$250M) is a fraction of its potential, with peak sales for smoking and vaping cessation possibly reaching $2–3 billion. I rate ACHV a strong buy, citing favorable approval odds and blockbuster potential, but note dilution and supply chain risks. Read the full article on Seeking AlphaIs Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement
Summary Achieve Life Sciences, Inc. initiated an open-label ORCA-OL trial using cytisinicline for smoking cessation; the Efficacy of the drug already established in several prior studies. Alignment with FDA that successful completion of ORCA-OL trial is necessary for NDA filing of cytisinicline in the 1st half of 2025. The global smoking cessation product market is estimated to reach $69.8 billion by the end of 2034. Potential label expansion opportunity exists of using cytisinicline for e-cigarettes or vaping cessation patients; End-of-phase 2 meeting expected in 2024. Read the full article on Seeking AlphaShareholder Returns
| ACHV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 20.9% | 1.0% | 1.1% |
| 1Y | 112.1% | 40.3% | 26.7% |
Return vs Industry: ACHV exceeded the US Biotechs industry which returned 44.4% over the past year.
Return vs Market: ACHV exceeded the US Market which returned 25.4% over the past year.
Price Volatility
| ACHV volatility | |
|---|---|
| ACHV Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACHV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ACHV's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 28 | Andrew Goldberg | www.achievelifesciences.com |
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol.
Achieve Life Sciences, Inc. Fundamentals Summary
| ACHV fundamental statistics | |
|---|---|
| Market cap | US$308.26m |
| Earnings (TTM) | -US$51.99m |
| Revenue (TTM) | n/a |
Is ACHV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACHV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$51.99m |
| Earnings | -US$51.99m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 140.0% |
How did ACHV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 05:13 |
| End of Day Share Price | 2026/05/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Achieve Life Sciences, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | Canaccord Genuity |
| null null | CG Capital |
| Gary Nachman | CGS International |